Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM1O3BY)

Drug Name
Mecasermin Drug Info
Synonyms Increlex (TN)
Indication
Disease Entry ICD 11 Status REF
Growth failure LD2F.1Y Approved [1]
Laron syndrome Investigative [2]
Therapeutic Class
Immunomodulatory Agents
Cross-matching ID
TTD Drug ID
DM1O3BY

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Insulin-like growth factor I receptor (IGF1R) TTHRID2 IGF1R_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Insulin-like growth factor I receptor (IGF1R) DTT IGF1R 4.542 5.508 6.35 5.558
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Growth failure
ICD Disease Classification LD2F.1Y
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Insulin-like growth factor I receptor (IGF1R) DTT IGF1R 1.64E-01 0.25 0.64
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
2 Cardiac examination in children with Laron syndrome undergoing mecasermin therapy. J Pediatr Endocrinol Metab. 2018 Jun 27;31(6):675-679.
3 IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows Arch. 2003 Aug;443(2):139-45.